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Objectives: 
 
to investigate whether in-ambulance abciximab initiation, in
ST-elevation myocardial infarction (STEMI) patients improves ST segment
resolution (STR) after primary percutaneous intervention (PCI).
 
Methods:
 
 MISTRAL is a prospective randomized double blind study con-
ducted in 11 centers in France (ClinicalTrial.gov number NCT 00638638). 256
patients with STEMI within 6 hours from symptom onset were allocated to
receive Abciximab started either in the Mobile Intensive Care Unit (MICU) or
later in the cathlab after diagnostic angiography. Other treatments in the MICU
included aspirin 250 mg IV, heparin 40 UI/kg IV. Primary endpoint was com-
plete (>70%) ST-segment resolution was adjudicated by an independent cen-
tralized ECG-Corelab.
 
Results: 
 
 mean age was 56 ± 12 years old and 80 % of the patients were
males. Median delay from symptoms to diagnosis was 90 min and 103 min
min from diagnosis to balloon. Complete ST resolution was similar in the
early and late groups 21% vs 15% (p=0.44) before PCI and 70 % vs 67%
(p=0.67) 60 min after PCI. Mean residual ST elevation tended to be lower in
the early group before PCI 8.1 vs 9.6 mm (P=0.17) but not after PCI 3.0 vs
3.2 mm (p=0.62). In the early group, TIMI 2-3 flow rate before PCI tended to
be higher (45 vs 34%, p=0.095 ) and distal embolisation rate was lower (8 vs
21%, p=0.008). TIMI 2-3 flow rate post-PCI, blush score rates, LVEF, bio-
logic infarct size, 30 days MACE were similar in both groups with very low
mortality rates (1.7 vs 0.8%).
 
Conclusions:
 
 early ambulance vs. routine cathlab administration of abcix-
imab in STEMI did not improve ST resolution post-PCI, final TIMI flow rate,
LVEF, infarct size and MACE. Early ambulance abciximab tended to improve
TIMI 2-3 flow rates pre-PCI and to reduce slow flow and distal embolisation
during procedure. Early abciximab tends to “facilitate” PCI procedure since
more arteries are opened at the time of angio (45 vs 34 % TIMI2-3) and less
embolisation or slow flow occurs during procedure.
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Iron deficiency in non-anemic heart failure patients.
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Background:
 
 Functional improvement has recently been reported in
anemic and non-anemic heart failure (HF) patients with biological iron defi-
ciency who were treated by intravenous iron substitution. Our aim was to
show whether the non-anemic patients with iron deficiency have poorer func-
tional tests than non-deficient ones. 
 
Method:
 
 We included 138 HF patients without anemia from our HF
department at Toulouse University Hospital into 2 groups: 1/ low ferritin rate
group (LFG) with a serum ferritin of 100 µg/L and lower (n=42), 2/  normal
ferritin rate group (NFG) with serum ferritin over 100 µg/L (n=96). We mea-
sured standard blood tests and functional parameters including NYHA status,
6 minute walk test (6’WT), and peak oxygen consumption (VO2max).
 
Results:
 
 Baseline patient characteristics showed a slight difference for
hemoglobin in non-anemic patients (LFG, 13.9; NFG, 14.4; p=0.04) who have
no difference for ejection fraction (LFG, 27.5%; NFG 29.5%; p=NS) between
groups. The iron deficient patients tend to be older (59 versus 63 yo, p=NS)
and most of them were women (92% in LFG versus 67% in NFG (p<0.05)). 
Functional parameters showed i) NYHA status of 2.29 in LFG versus 2.35
in NFG (p=NS); ii) 6’WT of 307m in LFG versus 361m in NFG (p=0.006);
and, iii) VO2max of 13.8ml/min/kg in LFG versus 15.7ml/min/kg for the NFG
(p=0.04). Moreover, the LFG had a higher creatinin rate of 145 µmol/l versus
107µmol/l for the NFG (p= 0.02).
 
Conclusion:
 
 Iron deficient patients have poorer functional tests and are
more likely to have renal insufficiency. Risk factors for iron deficiency in HF
are the age and the female sex. We put in light some risk factors for iron defi-
ciency that may help the practitioner making out which non-anemic HF
patients should have blood tests to look for iron deficiency.
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Purpose:
 
 When isolated and non immune, prevalence of congenital and
childhood atrioventricular blocks (AVB) is extremely low and little is known
about their natural history.
 
Methods:
 
 a multicentric study retrospective from 1980 to 2009 allowed
inclusion of 141 children from 13 French referral centers. Included children
presented an AVB diagnosed in utero, at birth or during childhood before the
age of 15 years, without structural heart abnormalities and without maternal
antibodies.
 
Results:
 
 26 congenital and 114 childhood AVB were included. Symptoms
lead to diagnosis in 15,6% whereas AVB was asymptomatic in 84,4%. 73%
AVB were complete and 26,2% AVB were incomplete at first presentation. 21
of these incomplete blocks (56,7%) progressed to permanent complete AVB.
Narrow QRS complexes were found in 69,2% congenital and 91,2% childhood
AVB. In the 112 (79,4%) implanted children, mean duration between AVB
diagnosis and pacemaker implantation was 35 months. Pacemaker primo-
implantation occurred during the first year of life for 18 children and 90 chil-
dren (63.8%) were paced before 10 years old. Pacing was required for symp-
tomatic bradycardia in 37,5% whereas prophylactic cardiac pacing accounted
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